Current state of systematic reviews for platelet-rich plasma use in knee osteoarthritis

Ref ID 1054
First Author G. Sahi
Journal ORTHOPAEDIC TRAUMATOLOGY SURGERY & RESEARCH
Year Of Publishing 2024
URL https://www.sciencedirect.com/science/article/abs/pii/S1877056823002712?via%3Dihub
Keywords • Musculoskeletal
• Low methodological quality
Problem(s) • Lack of prespecification in eligibility criteria
• Reasons for excluding potentially eligible studies not provided
• Conflicts of interest or funding of included studies not assessed
• Low methodological (AMSTAR) quality
Article Type Empirical
Article Subtype Cross-sectional survey/Methodological systematic review
First Author Country Canada
Checklists • AMSTAR 2
Aim To evaluate the methodological quality of systematic reviews (SRs) indexed across MEDLINE, EMBASE, PubMed and Cochrane databases from inception to May 2023, on platelet-rich-plasma therapy for knee osteoarthritis using AMSTAR 2.
Level of Investigation Descriptive
Summary of Findings From 41 included systematic reviews (SRs) indexed across MEDLINE, EMBASE, PubMed and Cochrane databases from inception to May 2023. Of the 41 SRs included in the analysis none were deemed high quality. Seven SRs (17%) were of “low” quality, while the remainder (34 SRs, 83%) were rated as “critically low”. The least reported items were: 1) 27/41 (65.8%) did not explain their selection of the study designs for inclusion in the review; 2) 37/41 (90.2%) did not provide a list of excluded studies with justifications; 3) 34/41 (82.9%) did not report on the sources of funding for the included studies; 4) 32/41 (78.0%) did not account for risk of bias in individual studies when interpreting/ discussing the results.
Number of systematic reviews included 41
Number of eligible systematic reviews assessed 576
Treatment impacted No
Treatment impacted description
Interpretation impacted Not Applicable
Interpretation impacted description